Tapentadol extended release (ER)

DRUG2 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions

Diabetic Neuropathy, PainfulDiabetic Peripheral NeuropathyDiabetic Polyneuropathy

Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

CompletedNCT01041859

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetic Peripheral Neuropathy

Start: 2009-12-31End: 2011-03-31Updated: 2013-09-11

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

TerminatedNCT01063868

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetic Neuropathy, Painful, Diabetic Polyneuropathy

Start: 2010-01-31End: 2010-06-30Updated: 2014-03-04

Related Papers

A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy.

2015-02-0131 citations